ENFLONSIA DIN 02565145
Health Canada record
| Active ingredient(s) | CLESROVIMAB 105 MG |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J06BD10 CLESROVIMAB |
| Original market date | |
| Current status date | 30-Jan-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36842 | 2026-01-30 | New Drug Submission (NDS) |